1937 Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG phase III planB trial. (September 2015) - Gluz, O.; Nitz, U.; Kreipe, H.H.; Christgen, M.; Kates, R.E.; Hofmann, D.; Shak, S.; Clemens, M.; Kraemer, S.; Aktas, B.; Kuemmel, S.; Reimer, T.; et al.